IMRN vs JNJ

The deterministic health profile is weak, headlined by a Piotroski F-Score of 3/9, indicating significant financial deterioration. While the company maintains a strong liquidity position with a Current Ratio of 8.04 and negligible debt (D/E 0.02), these are offset by severe operational losses and a profit margin of -62.14%. The stock is in a clear long-term downtrend, losing over 85% of its value over five years, and the lack of recent earnings data suggests a lack of transparency or momentum. Despite trading below book value (P/B 0.70), the fundamental decay outweighs the valuation discount.

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.